Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Deeper DNA analysis may unlock better cancer care

NCT ID NCT04614480

Knowledge-focused Sponsor: Centre Georges Francois Leclerc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing whether a more detailed genetic analysis of tumors (called 'complex' exome analysis) helps doctors choose better treatments for people with advanced solid tumors compared to a standard genetic analysis. About 8,000 participants will have their tumor and normal DNA analyzed. The goal is to see if the complex analysis leads to treatments that would not have been possible with the simpler test.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Exome analysis (genetic testing of tumor and normal DNA)
What this could lead to
If successful, this could show that a more detailed genetic analysis helps doctors select better, more personalized cancer treatments from the start.
What could go wrong
This is a Phase 2 study, so it is still early. The extra genetic information may not actually improve treatment decisions or patient outcomes. The results may not apply to all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 7,976 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2020

Expected to finish

Sep 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years old 2. Weight\> 30 Kg 3. Histological or cytological evidence of the diagnosis of a metastatic or locally advanced solid tumor 4. Patient in 1st line of treatment for metastatic or locally advanced disease 5. Tumor material available in sufficient and usable quantity for the analyzes required by the study 6. Request for exome analysis to be carried out when initiating the 1st or 2nd line of treatment (line initiated at the time of inclusion) 7. Life expectancy estimated to be probably ≥ 6 months. 8. WHO ≤ 1 9. Patient capable and willing to follow all study procedures in accordance with the protocol 10. Patient having understood the purpose, risks and constraints of the study and having signed and dated the consent form 11. Patient affiliated to the social security scheme. Exclusion Criteria: 1. Tumor material not available or biopsy not possible. 2. Inability to take a blood test. 3. Refusal of genetic analysis. 4. Patient likely to progress within 3 months of inclusion in the study. 5. History of HIV / HBV / HCV infection. 6. Patient already included in the EXOMA or EXOMA2 study. 7. Woman who is pregnant, may be, or is breastfeeding. 8. Persons deprived of their liberty or under guardianship (including curatorship).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CGFL

    RECRUITING

    Dijon, 21079, France

  • CHRU Jean Minjoz

    RECRUITING

    Besançon, France

  • CHU Amiens Picardie

    NOT_YET_RECRUITING

    Amiens, France

  • CHU François Mitterrand

    RECRUITING

    Dijon, France

  • CHU Nantes

    TERMINATED

    Nantes, France

  • Centre Eugène Marquis

    RECRUITING

    Rennes, France

  • Centre Henri Baclesse

    RECRUITING

    Caen, France

  • Centre Oscar Lambret

    RECRUITING

    Lille, France

  • Chu Poitiers

    TERMINATED

    Poitiers, France

  • Institut Bergonie

    TERMINATED

    Bordeaux, France

  • Institut Hospitalier Franco-Britannique

    TERMINATED

    Levallois-Perret, France

  • Institut JeanGodinot

    RECRUITING

    Reims, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.